Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TPH1 | P17752 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.47 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.43 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21690086 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2TPH1SLC6A2SLC6A4 | |
| SCHEMBL5720938 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2TPH1SLC6A2SLC6A4 | |
| SCHEMBL31165823 | 1.00 | KMT2A (0.55) | KMT2ASMN1; SMN2TPH1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL6951450 | 0.98 | KMT2A (0.54) | KMT2ASMN1; SMN2TPH1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL23001124 | 0.86 | TPH1 (0.55) | KMT2ASMN1; SMN2TPH1SLC6A2SLC6A4 | |
| SCHEMBL17545259 | 0.85 | KMT2A (0.48) | KMT2ASMN1; SMN2TPH1CYP3A4CYP2D6 | |
| SCHEMBL7450034 | 0.83 | HDAC1 (0.49) | TPH1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL12320565 | 0.82 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL657936 | 0.82 | GABBR2 (0.50) | SLC6A2SLC6A4SLC6A3KCNH2CYP3A4 | |
| SCHEMBL2294505 | 0.81 | TNF (0.45) | KMT2ASMN1; SMN2TPH1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | claimed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | claimed |
| US-20220242914-A1 | PEPTIDES AND USE THEREOF | SYNTHERIX LIMITED (GB) | 2022-08-04 | — | — | US | claimed |
| EP-3947418-A2 | PEPTIDES AND USE THEREOF | Warenius, Hilmar M (GB) | 2022-02-09 | — | — | EP | claimed |
| WO-2020193978-A2 | PEPTIDES AND USE THEREOF | WARENIUS HILMAR (GB) | 2020-10-01 | — | — | WO | claimed |
| CN-109790523-A | composition and use thereof | 希尔马·M·瓦雷纽斯 | 2019-05-21 | — | — | CN | claimed |
| EP-3414326-A1 | COMPOSITIONS AND USES THEREOF | Warenius, Hilmar M (GB) | 2018-12-19 | — | — | EP | claimed |
| CN-107406485-A | Peptides for the Treatment of Cancer | 希尔马·M·瓦雷纽斯 | 2017-11-28 | — | — | CN | claimed |
| WO-2017137761-A1 | COMPOSITIONS AND USES THEREOF | WARENIUS HILMAR M (GB) | 2017-08-17 | — | — | WO | claimed |
| EP-3177716-A1 | PEPTIDES USEFUL FOR TREATING CANCER | Warenius, Hilmar M (GB) | 2017-06-14 | — | — | EP | claimed |
| WO-2016020437-A1 | PEPTIDES USEFUL FOR TREATING CANCER | WARENIUS HILMAR M (GB) | 2016-02-11 | — | — | WO | claimed |
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | SYNTHERIX LIMITED (GB) | 2026-03-10 | — | — | US | disclosed |
| WO-2024200264-A1 | PEPTIDES AND USES THEREOF | SYNTHERIX LIMITED (GB) | 2024-10-03 | — | — | WO | disclosed |
| EP-3947418-B1 | PEPTIDES AND USE THEREOF | SYNTHERIX LTD (GB) | 2024-04-03 | — | — | EP | disclosed |
| EP-0393441-A1 | Mercapto-acylamino acids | SCHERING CORPORATION (US) | 1990-10-24 | — | — | EP | disclosed |
| WO-1990012003-A1 | MERCAPTO-ACYLAMINO ACIDS | SCHERING CORPORATION (US) | 1990-10-18 | — | — | WO | disclosed |
| CN-1043125-A | Be used as the aryl urea of the replacement of high-potency sweetener | NUTRASWEET CO (US) | 1990-06-20 | — | — | CN | disclosed |
| WO-1990002112-A1 | SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS | THE NUTRASWEET COMPANY (US) | 1990-03-08 | — | — | WO | disclosed |
| EP-0355819-A1 | Substituted aryl ureas as high potency sweeteners | THE NUTRASWEET COMPANY (a Delaware corporation) (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570697-B2 | Cyclic peptide useful in the treatment of cancer | NPR1, NPR3, PTMS | KMT2A 4508/4885SMN1; SMN2 1585/4885TPH1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.